First Trust Nasdaq Pharmaceuticals ETF FTXH

Medalist Rating as of | See First Trust Investment Hub

Morningstar’s Analysis FTXH

Will FTXH outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

First Trust Nasdaq Pharmaceuticals ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FTXH

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 52.1
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

7.57 3M
Healthcare

AbbVie Inc

7.29 3M
Healthcare

Johnson & Johnson

7.06 3M
Healthcare

Merck & Co Inc

6.74 2M
Healthcare

Bristol-Myers Squibb Co

6.31 2M
Healthcare

Viatris Inc

3.77 1M
Healthcare

Cardinal Health Inc

3.47 1M
Healthcare

Biogen Inc

3.46 1M
Healthcare

Vertex Pharmaceuticals Inc

3.31 1M
Healthcare

Amgen Inc

3.16 1M
Healthcare

Sponsor Center